Given the direct correlation between synaptic plasticity and cognitive impairment in AD, therapeutic strategies built on “ACSS2/histone acetylation/glutamate receptor” will provide novel perspectives for the treatment of AD. The gene discussed is ACSS2; the disease is Cognitive impairment.